ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ENVB
FBLG (36) XCUR (32) APRE (40) BGMS (38) ⌘ Pro Terminal →

Enveric Biosciences Inc. (ENVB) — RQD Stock Rating Cockpit

$1.45 +1.40% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.45

Enveric Biosciences Inc. (ENVB) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $6.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ENVB Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ENVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Enveric Biosciences Inc. (NASDAQ: ENVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.45 (+1.40% 1D, market cap $6.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ENVB ranks #654 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ENVB compare to FBLG and XCUR in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENVB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.6M). Among the 5-stock peer group, ENVB leads on earnings multiple (N/A) while ENVB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ENVB?
▼

Per ENVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000890821), Enveric Biosciences Inc. generated $24.6M in revenue (-8.9% YoY), $12.1M in net income, and -$8.1M in free cash flow against $5.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.45 (+0.06%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (4)Whales (6)SEC (10)Macro (9)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11% Base Target
$14 Bull$1 Base$1 Bear
📬 FREE ENVB RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ENVB)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY ENVB SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 48.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$1.40+2.9% Next Q
Q2 (-2Q)
29
Grade E$1.44-1.4% Next Q
Q3 (-1Q)
31
Grade E$1.42+2.1% Next Q
Current
34
Grade E$1.45-8.7% Hist 90D α
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ENVB Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ENVB currently carries a cautious 34/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.46) and Max Pain ($1.52) forces dealer call-delta covering toward $13.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ENVB• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ENVB Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
48.230 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $1$1.45H: $13
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 19 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on ENVB

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (33)

11/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like ENVB
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ENVB)

  • ✓Walkthrough of ENVB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ENVB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.48%⚡ TESTING RESISTANCE
2026-11-03O $1.46H $1.46L $1.43C $1.45VOL 12.0K
RES: $1.56SUP: $1.32SMA50: $1.46SMA200: $1.99
$6.92$5.36$3.80$2.24$0.69RES $1.56SUP $1.32$1.452026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ENVB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ENVB Butterfly Map → + Track ENVB →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -8.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ENVB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ENVB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ENVB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ENVB)

Health Care Rank #654 of 1015 ⚔️ FBLG vs ENVB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ENVB vs. FBLG, XCUR, APRE, BGMS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Enveric Biosciences Inc. (ENVB) ranks #654 by composite RQD confidence (34/100, grade E) and #923 by equity capitalization ($6.4M). Within this direct 5-issuer industry benchmark cohort, ENVB leads on earnings valuation at N/A trailing P/E, while ENVB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APRE currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with ENVB at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ENVB ACTIVE
Enveric Biosciences Inc.
E 34/100 — — -35.0% +1.40% $6.4M Benchmark Subject
FBLG
FibroBiologics Inc.
D- 36/100 — — -35.0% -1.06% $6.3M /fblg-vs-envb →
XCUR
Exicure Inc.
E 32/100 — — -35.0% +0.99% $6.6M /xcur-vs-envb →
APRE
Aprea Therapeutics Inc.
D- 40/100 — — -35.0% +1.32% $6.1M /apre-vs-envb →
BGMS
Bio Green Med Solution Inc.
D- 38/100 — — -35.0% 0.00% $6.0M /bgms-vs-envb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000890821 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Enveric Biosciences Inc. (ENVB) reported GAAP revenue of $24.6M (-8.9% vs. FY2024 revenue of $27.0M , and -46.7% cumulative change since FY2023) , GAAP net income of $12.1M, operating cash flow of -$8.1M, and free cash flow of -$8.1M (-5.4% YoY). On the balance sheet, ENVB closed FY2025 with $5.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $24.6M $12.1M -$8.1M -$8.1M $5.1M —
FY2024 (FY) 2024-12-31 $27.0M $9.6M -$7.7M -$7.7M $3.1M —
FY2023 (FY) 2023-12-31 $46.1M $17.5M -$14.1M -$14.1M — —

3. ENVB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ENVB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Enveric Biosciences Inc. (NASDAQ: ENVB) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.45 (+1.40% 1D, market cap $6.4M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, ENVB ranks #654 in composite RQD confidence.

How does ENVB compare to FBLG and XCUR in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ENVB carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, FBLG (FibroBiologics Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $6.3M) and XCUR (Exicure Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $6.6M). Among the 5-stock peer group, ENVB leads on earnings multiple (N/A) while ENVB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ENVB?

Per ENVB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000890821), Enveric Biosciences Inc. generated $24.6M in revenue (-8.9% YoY), $12.1M in net income, and -$8.1M in free cash flow against $5.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ENVB trading relative to its 50-day, 200-day, and 52-week technical levels?

ENVB last traded at $1.45 (+1.40% on volume of 28,404 shares), positioning the stock -0.68% below its 50-day simple moving average ($1.46) and -27.14% below its 200-day simple moving average ($1.99). Across its 52-week range of $1.17 to $13.25, ENVB sits at the 2.3% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.27 to $1.63).

Direct Sub-Reports: ENVB RQD Cockpit ENVB 12M Forecast ENVB Earnings & Move ENVB Dividends & DRIP ENVB Insiders & 13F ENVB Whale Options ENVB Profit Sankey ENVB News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

ENVB — Enveric Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Enveric Biosciences Inc. (ENVB) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.45 (+1.40% 1D, market capitalization $6.4M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Enveric Biosciences Inc. (ENVB) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. The company operates as a biotechnology issuer.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Enveric Biosciences Inc. (ENVB) reported $24.6M in annual revenue (up from $27.0M in FY2024, -8.9% YoY) and $12.1M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($46.1M revenue, $17.5M net income) through FY2025, ENVB scaled operating cash flow to -$8.1M and free cash flow to -$8.1M, backed by $5.1M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $1.17 – $13.25 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

There are no upstream or downstream links, no sector-correlation links, and no proprietary signals.

  • Key Question #1: Can ENVB sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $24.6M and free cash flow of -$8.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ENVB's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ENVB Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Enveric Biosciences Inc. (ENVB) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ENVB Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ENVB Bull vs. Bear Conversation Board — What's Your Call at $1.45?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ENVB 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ENVB:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $1.74 (+21.7%)
📌 Pinned Debate

Recent news wire items report favorable preclinical results and positive IND-enabling ADMET study outcomes for a psychiatric candidate.

Picked up a starter position in ENVB in my $100K Virtual Cash book at $1.43. Recent news wire items report favorable preclinical results and positive IND-enabling ADMET study outcomes for a psychiatric candidate.. Trading inside a $1.17–$13.25 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

ArenaChamp_24 🐂 BULL

@FadeTheHype Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.22 (-14.7%)
Spot @ $1.43

ROIC of -35% and 0% FCF yield, with negative operating income in every reported period, show no current cash generation to support the

ROIC of -35% and 0% FCF yield, with negative operating income in every reported period, show no current cash generation to support the valuation.. Look at the math on ENVB: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $1.26 before getting long.

LIVE TAPE